Table 3:
Hospital outcomes
| Number of subjects (%) | |
|---|---|
| MASCC score | |
| Median (range) | 21 (10–26) |
| Low (% ≥ 21) | 18 (58%) |
| Antibiotic monotherapy at admission | 12 (39%) |
| Antibiotics administered at admission | |
| Ceftazidime | 3 (10%) |
| Piperacillin/Tazobactam | 11 (35%) |
| Carbapenem | 4 (13%) |
| Cefepime | 14 (45%) |
| Vancomycin | 15 (49%) |
| Other | 4 (13%) |
| Positive culture | |
| None | 14 (45%) |
| One | 16 (52%) |
| Two | 1 (3%) |
| Type of positive culture among patients with a positive culture (n=17) | |
| Urine | 3 (18%) |
| Blood | 3 (18%) |
| Sputum | 0 |
| Abscess/drain | 2 (12%) |
| Other | 9 (53%) |
| Severe complication | 7 (23%) |
| Death | 0 |
| Hypotension | 4 (13%) |
| Respiratory/renal failure | 0 |
| ICU admission | 2 (6%) |
| Confusion or ΔMS | 3 (10%) |
| Congestive cardiac failure | 0 |
| Bleeding requiring transfusion | 1 (3%) |
| EKG changes | 0 |
| Arrhythmia requiring treatment | 0 |
| Fungal infection | 0 |
| Allergic reaction | 0 |
| Discharged on antibiotics | 20 (65%) |
| Days of hospitalization (median, days) | 4 (range, 2–13) |
*
MASCC: Multinational Association of Supportive Care in Cancer; ICU: intensive care unit; MS: mental status; EKG: electrocardiogram